Amgen related Press Releases
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452Cytokinetics Receives Exercise Fee of $50 Million; Cytokinetics to Host a
... Read more...Amgen Highlights Data to Be Presented at ASCO
Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign 'Coping with Cancer from the Outside In' Program to Launch at the Annual Oncology Nursing Society Congress THOUSAND OAKS,
... Read more...FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab THOUSAND OAKS, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Amgen Inc. (NASDAQ:AMGN) today announced that the U.S.
... Read more...Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and
... Read more...Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe Hands-On Science Research Program Expansion Brings the Amgen Foundation's Total Commitment to Amgen Scholars to
... Read more...Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Amgen Positioned to Deliver Attractive Growth Over Next Five Years NEW YORK, November 07, 2008 /PRNewswire-FirstCall/ -- At an Amgen meeting of about 200 securities analysts and investors in New York
... Read more...Amgen's Third Quarter 2008 Adjusted Earnings, Third Quarter 2008 Revenue Increase
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges




